Uterine Abnormalities Flashcards

1
Q

Define uterine fibroids

A

Benign tumour of the uterine smooth muscle (leiomyoma), i.e of the myometrium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Classify the different types of fibroids based on location

A
Based on location relative to the uterine wall 
•	Submucous  
•	Cervical  
•	Intramural  
•	Subserosal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the macroscopic appearance of fibroids?

A

Looks like a well-demarcated, firm, whorled tumour

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Outline the aetiology of fibroids

A

Hormone dependent: contain lots of oestrogen and progesterone receptors

  • Enlarge in pregnancy (due to oestrogen), shrink in menopause
  • Cause known
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Outline some risk factors and protective factors for developing fibroids

A

RF: nulliparity, family history, obesity, smoking, afro-carib, HRT causing continued fibroid growth following menopause

Protective: smoking, parous women, long term hormonal contraceptive use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Outline 3 different types of fibroid degeneration (occur when the fibroids outgrow their blood supply) that can occur in its natural history

A

Red degeneration:
• Haemorrhage and necrosis occurs within the fibroid typically presenting in the mid-second trimester pregnancy with acute pain

Hyaline degeneration:
• Asymptomatic softening and liquefaction of the fibroid

Cystic:
• Asymptomatic central necrosis leaving cystic spaces at the centre
• Degenerative changes can initiate calcium deposition leading to calcification
• Suspicion is greatest in the postmenopausal period when there is rapidly increasing size of the fibroid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Give some symptoms that can be clinically present due to fibroids

A
  • None (50%)

Symptoms are mainly related to location rather than size

  • Menorrhagia (more likely in submucosal, polypoid)
  • Erratic bleeding (IMB)
  • Pressure effects: pressure sensation, bladder/bowel defects
  • Subfertility (tubal ostia blockage, submucous fibroids blocking implantation)
  • Pain (rarely cause pain, unless torso or red degeneration occurs)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Give some signs of fibroids on physical examination

A

On examination
o Abdo – palpable pelvic mass, continuous with uterus
o Vaginal – enlarged, firm, smooth or irregular non-tender uterus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Outline investigations for fibroids

A
  • Bloods – FBC – anaemia
  • USS – TVUS
  • Other – hysteroscopy if submucosal, MRI if diagnosis is unclear/greater accuracy required
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What needs to be considered when deciding treatment strategies for fibroids?

A

?Symptomatic
?Functional impact on QoL
?Desire for fertility
?Desire for preservation of uterus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Outline medical treatment for fibroids

A

Main treatments for HMB
• LNG-IUS (levonorgestrel/progesterone intrauterine system)
• Tranexamic acid/Mefenamic acid
• COCP
These treatments are mainly effective in women with HMB without fibroids, but can be worth trying first-line

Injectable GnRH Agonist
• Only effective medical treatment
• Induces a menopausal state (shuts down ovarian oestradiol production)
• Poorly tolerated because of side effects and bone density loss (can only be used for 6 months)

Ulipristal Acetate (selective progesterone receptor modulator, SPRM)
• As effective as GnRH agonists in reducing fibroid volume and alleviating HMB symptoms
• Not yet widely accepted into clinical practice
• Does NOT induce a menopausal state (therefore no GnRH agonist side effects)
• Can be taken orally
NOTE: neither of the last two options are long-term as fibroids regrow as soon as ovarian function returns

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Outline surgical management for fibroids

A

Hysteroscopic surgery (minimally invasive)

  • Fibroid polyps
  • Small (up to 3cm) submucous fibroids

Myomectomy (open or laparoscopic)

  • If medical treatment has failed, but preservation of reproductive function is required
  • Preceded by 2-3 months of GnRH agonists/ulipristal acetate to shrink fibroid
  • Risk of bleeding, which may then require hysterectomy
  • Adhesions can form at site of myomectomy - can affect fertility (C-sections recommended for future pregnancies to prevent uterine rupture)

Hysterectomy (laparoscopic, vaginally or abdominally)

  • Preceded by 2-3 months of GnRH agonists/ulipristal acetate
  • Not suitable for women wanting to preserve fertility
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Outline radiological treatment for fibroids

A

Uterine artery embolisation (UAE)
• Embolisation of both uterine arteries under radiological guidance, to shrink fibroids
• Shorter hospital stay
• Complications: fever, infection, fibroid expulsion, potential ovarian failure
• Adequate counselling is important because the effect on reproductive function are uncertain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Give some complications of fibroids

A
  • Degenerations
  • Malignancy (~0.1% of fibroids are leiomyosarcomas)
  • Anaemia, miscarriage, infertility
  • In pregnancy: premature labour, transverse lie, PPH (should not be removed at C-section as bleeding may be heavy)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Under what conditions are malignant fibroids more likely

A
  • Pain and rapid growth
  • Growth in postmenopausal women not on HRT
  • Poor response to GnRH agonist or ulipristal acetate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Outline the prognosis with fibroids

A
  • 10 year recurrence rate after myomectomy is 20%

- Fibroids regress and calcify after menopause

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Define adenomyosis

A

Presence of endometrium and its underlying storm within the myometrium

18
Q

Give some risk factors for developing adenomyosis

A

Most common around 40 yrs

Associated with endometriosis and fibroids

19
Q

Outline the aetiology of adenomyosis

A

Oestrogen dependent
Cause unknown
Effects on fertility are unclear

20
Q

Outline the clinical features of adenomyosis

A

History: asymptomatic, painful, regular HMB may be common
Examination: uterus mildly enlarged and tender

21
Q

What investigations are undertaken for adenomyosis

A
  • Ultrasound

- Clearly diagnosed on MRI

22
Q

Outline the management for adenomyosis

A

Medical treatment (for menorrhagia)

  • Progesterone IUS
  • COCP +/- NSAIDs
  • Trial of GnRH analogue to determine if symptoms attributed to adenomyosis will improve with hysterectomy

Surgical
- Hysterectomy

23
Q

What is endometritis?

A

Inflammation of the endometrial lining

24
Q

Give some risk factors for developing endometritis

A

Occurs secondary to:

  • STIs
  • Complications of surgery (C-section, surgical termination)
  • Foreign tissue (IUDs)
  • Retained products of conception
  • Malignancy (particularly in postmenopausal uterus)
25
What is the treatment for endometritis?
- Antibiotics | - Occasionally ERPC (evacuation of retained products of conception) is required
26
Outline the aetiology of intrauterine polyps
- Benign tumours that grow into uterine cavity (most are endometrial, some are sub mucous fibroids) - Common when oestrogen levels are high - Post-menopausally: often found in pts on tamoxifen for breast cancer
27
Outline the symptoms of intrauterine polyps, and how it is diagnosed
- Sometimes asymptomatic - Menorrhagia, IMB - Can prolapse through the cervix Diagnosis: - Ultrasound - During hysteroscopy due to abnormal bleeding
28
How are intrauterine polyps treated?
- Resection (cutting diathermy or avulsion)
29
What is haematometra?
Menstrual blood accumulating in the uterus due to outflow obstruction
30
Define endometrial cancer
Malignancy arising from endometrial tissue
31
Give the two main subtypes of endometrial cancer
Type 1: endometrioid adenocarcinomas • Oestrogen-driven, associated with obesity, less aggressive • Arise from a background of endometrial hyperplasia Type 2: high-grade serous and clear cell carcinomas • Not oestrogen sensitive, not associated with obesity and more aggressive • Arise from an atrophic endometrium
32
Outline risk factors for the development of endometrial cancer
Main risk factor is exposure to oestrogen (endogenous or exogenous) Exogenous - Oestrogen-only HRT, tamoxifen (oestrogen agonist in postmenopausal women) Endogenous - Nulliparity or infertility (due to increase number of anovulatory cycles) - Early menarche/late menopause (also related to number of anovulatory cycles) - PCOS, oestrogen producing ovarian tumours (granulosa/theca) - Obesity (aromatisation of fat-derived peripheral androgens) - Diabetes (?due to raised BMI)
33
Outline the main epidemiology of endometrial cancer
- Prevalence highest at 60 years of age | - Only 15% of cases occur premenopausally, with <1% occurring before the age of 35
34
Describe the premalignant stages of disease in endometrial cancer
- Oestrogen acting unopposed --> hyperplasia of endometrium - -> Abnormalities of cellular/glandular architecture --> atypical hyperplasia If diagnosis of endometrial hyperplasia with atypic is made, hysterectomy should be considered. If fertility is a concern, try P-IUS with 6 monthly hysteroscopy and endometrial biopsy
35
Outline the clinical features of endometrial cancer
History: - PMB (10% RISK OF CARCINOMA) - perform speculum to rule out vulval, vaginal, cervical carcinoma - Premenopausal: IMB, recent onset menorrhagia - Other symptoms: abdominal pain, urinary dysfunction, bowel disturbance Examination: - May be normal - Bimanual: bulky uterus probable
36
Describe the FIGO staging system for endometrial cancer (1-4b)
Stage 1 (confined to uterus) - 1a: <1/2 myometrial invasion - 1b: >1/2 myometrial invasion Stage 2 - Cervical stromal invasion, but not beyond uterus Stage 3 (invades through the uterus) - 3a: serosa or adnexae - 3b: vaginal and/or parametrium - 3ci: pelvic node - 3cii: para-aortic node Stage 4 (further spread) - 4a: bowel or bladder - 4b: distant mets In addition, grades 1-3 are classified (grade 1 is well-differentiated)
37
Outline investigations for endometrial cancer
- Bloods: FBC, U&E, LFT, glucose testing (to assess baseline fitness of patient) - Imaging: pelvic USS, TVUS (depth of myometrial invasion, if <4mm very unlikely to be EC), MRI (staging), CXR (pulmonary spread) - Tissue diagnosis: pipelle biopsy, hysteroscopy and biopsy
38
Outline the stages of management for endometrial cancer
Surgery (abdominal or laparoscopic) - Stage 1 – total abdominal hysterectomy (TAH) with bilateral salpingo oophorectomy (BSO) with peritoneal washings - Stage 2/3 – modified radical or radical hysterectomy - Pelvic/para-aortic lymphadenectomy may be required Adjuvant therapy (following surgery) - External beam radiotherapy (in patients considered high risk for LN involvement) - Vaginal vault radiotherapy (reduces local recurrent rate, but does not improve survival) - Chemotherapy Hormone Treatment • High-dose oral or intrauterine progestins • Useful for women with complex atypical hyperplasia and low-grade stage 1A endometrial tumours • May be suitable for women who are not fit for surgery or want to avoid surgery for fertility reasons
39
What is the management approach for pre-menopausal women with endometrial cancer who want to preserve their fertility?
Mainly in PCOS causing endometrial cancer pts * Alternatives to hysterectomy: only possible for pre-cancer or early-stage low-grade endometrial cancers * Hormone therapy (oral progestogens or LNG-IUS): but associated with high relapse rates Referral to a specialist to discuss ovarian conservation and/or stimulation for egg retrieval and surrogacy
40
Outline the prognosis for endometrial cancer
``` 5-year survival rates Stage 1: 90 Stage 2: 75 Stage 3: 60 Stage 4: 25 Overall: 75 ``` Recurrence is most common with vaginal vault radiotherapy Poor prognostic factors: older age, advanced stage, deep myometrial invasion, high grade